These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 25603916)

  • 21. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates.
    Biolchi A; De Angelis G; Moschioni M; Tomei S; Brunelli B; Giuliani M; Bambini S; Borrow R; Claus H; Gorla MCO; Hong E; Lemos APS; Lucidarme J; Taha MK; Vogel U; Comanducci M; Budroni S; Giuliani MM; Rappuoli R; Pizza M; Boucher P
    Vaccine; 2020 Nov; 38(47):7542-7550. PubMed ID: 33036804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
    Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
    Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland.
    Bodini M; Brozzi A; Giuliani M; Nohynek H; Vainio A; Kuusi M; De Paola R; Pizza M; Medini D; Toropainen M; Serino L; Muzzi A
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.
    Esposito S; Principi N
    Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.
    Domnich A; Gasparini R; Amicizia D; Boccadifuoco G; Giuliani MM; Panatto D
    J Immunol Res; 2015; 2015():353461. PubMed ID: 26351645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Controlling serogroup B invasive meningococcal disease: the Canadian perspective.
    Bettinger JA; Deeks SL; Halperin SA; Tsang R; Scheifele DW
    Expert Rev Vaccines; 2013 May; 12(5):505-17. PubMed ID: 23659299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progressive decrease in the potential usefulness of meningococcal serogroup B vaccine (4CMenB, Bexsero®) in Gipuzkoa, Northern Spain.
    Pérez-Trallero E; Esnal O; Marimón JM
    PLoS One; 2014; 9(12):e116024. PubMed ID: 25541709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016.
    Soeters HM; Dinitz-Sklar J; Kulkarni PA; MacNeil JR; McNamara LA; Zaremski E; Chang HY; Lujan E; Granoff D; Lasky M; Montana B
    Emerg Infect Dis; 2017 May; 23(5):867-869. PubMed ID: 28418307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meningococcal B vaccination: real-world experience and future perspectives.
    Kuhdari P; Stefanati A; Lupi S; Valente N; Gabutti G
    Pathog Glob Health; 2016; 110(4-5):148-56. PubMed ID: 27309042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
    Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
    Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
    Masignani V; Pizza M; Moxon ER
    Front Immunol; 2019; 10():751. PubMed ID: 31040844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.
    Vogel U; Taha MK; Vazquez JA; Findlow J; Claus H; Stefanelli P; Caugant DA; Kriz P; Abad R; Bambini S; Carannante A; Deghmane AE; Fazio C; Frosch M; Frosi G; Gilchrist S; Giuliani MM; Hong E; Ledroit M; Lovaglio PG; Lucidarme J; Musilek M; Muzzi A; Oksnes J; Rigat F; Orlandi L; Stella M; Thompson D; Pizza M; Rappuoli R; Serruto D; Comanducci M; Boccadifuoco G; Donnelly JJ; Medini D; Borrow R
    Lancet Infect Dis; 2013 May; 13(5):416-25. PubMed ID: 23414709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents.
    Biolchi A; Tomei S; Santini L; La Gaetana R; Mori E; Novy P; Rappuoli R; Bekkat-Berkani R; Giuliani MM; Pizza M
    Pediatr Infect Dis J; 2021 Feb; 40(2):e66-e71. PubMed ID: 33060520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Princeton University can import vaccine to combat meningitis outbreak.
    Clin Infect Dis; 2014 Feb; 58(3):i. PubMed ID: 24571006
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunogenicity of a Meningococcal B Vaccine during a University Outbreak.
    Basta NE; Mahmoud AA; Wolfson J; Ploss A; Heller BL; Hanna S; Johnsen P; Izzo R; Grenfell BT; Findlow J; Bai X; Borrow R
    N Engl J Med; 2016 Jul; 375(3):220-8. PubMed ID: 27468058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.
    Muzzi A; Brozzi A; Serino L; Bodini M; Abad R; Caugant D; Comanducci M; Lemos AP; Gorla MC; Křížová P; Mikula C; Mulhall R; Nissen M; Nohynek H; Simões MJ; Skoczyńska A; Stefanelli P; Taha MK; Toropainen M; Tzanakaki G; Vadivelu-Pechai K; Watson P; Vazquez JA; Rajam G; Rappuoli R; Borrow R; Medini D
    Vaccine; 2019 Feb; 37(7):991-1000. PubMed ID: 30661831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.